Patents by Inventor Kevin Bacon

Kevin Bacon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090286771
    Abstract: Provided herein are 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity. These compounds are useful for the treatment of diseases associated with CCR3 activity, including but not limited to, atopic dermatitis, allergic rhinitis, rheumatoid arthritis, Grave's disease, HIV infection, Alzheimer's disease, atherosclerosis and other inflammatory and/or immunological disorders.
    Type: Application
    Filed: July 16, 2009
    Publication date: November 19, 2009
    Inventors: Yingfu Li, Kevin Bacon, Hiromi Sugimoto, Keiko Fukushima, Kentaro Hashimoto, Makiko Marumo, Toshiya Moriwaki, Noriko Nunami, Naoki Tsuno, Klaus Urbahns, Nagahiro Yoshida
  • Publication number: 20090270388
    Abstract: The present invention relates to novel fused azolepyriimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-? inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-? activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoimmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis.
    Type: Application
    Filed: March 30, 2009
    Publication date: October 29, 2009
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Mitsuyuki Shimada, Toshiki Murata, Kinji Fuchikami, Hideki Tsujishita, Naoki Omori, Issei Kato, Mami Miura, Klaus Urbahns, Florian Gantner, Kevin Bacon
  • Patent number: 7511041
    Abstract: The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-? inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-? activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis.
    Type: Grant
    Filed: September 18, 2003
    Date of Patent: March 31, 2009
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Mitsuyuki Shimada, Toshiki Murata, Kinji Fuchikami, Hideki Tsujishita, Naoki Omori, Issei Kato, Mami Miura, Klaus Urbahns, Florian Gantner, Kevin Bacon
  • Publication number: 20090054424
    Abstract: An optically active (?)-7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-5-[(3S)-3-piperidinyl]-1,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one of the formula: or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.
    Type: Application
    Filed: May 19, 2008
    Publication date: February 26, 2009
    Inventors: Toshiki Murata, Sachiko Sakakibara, Takashi Yoshino, Hiroki Sato, Yuji Koriyama, Noriko Nunami, Megumi Yamauchi, Keiko Fukushima, Rolf Grosser, Kinji Fuchikami, Kevin Bacon, Timothy Lowinger
  • Publication number: 20090012102
    Abstract: The present invention relates to an imidazo[1,2-c]pyrimidinylacetic acid derivative and salts thereof which is useful as an active ingredient of pharmaceutical preparations.
    Type: Application
    Filed: January 19, 2005
    Publication date: January 8, 2009
    Applicant: Actimis Pharmaceuticals, Inc.
    Inventors: Tai-wei Ly, Takashi Yoshino, Yuki Takekawa, Takuya Shintani, Hiromi Sugimoto, Kevin Bacon, Klaus Urbahns
  • Publication number: 20080264499
    Abstract: A hydraulic control system for a machine is disclosed. The hydraulic control system may have a source driven by an engine to pressurize fluid, and a tool actuator movable by pressurized fluid. The hydraulic control system may further have a first valve element movable to control an amount of pressurized fluid directed to the tool actuator, and an interface device movable by an operator to control an amount of pressurized fluid directed to move the first valve element. The hydraulic control system may also have a second valve element movable to limit an amount of pressurized fluid available to move the first valve element, and a controller in communication with the second valve element. The controller may be configured to move the second valve element to reduce pressurized fluid directed to the first valve element in an amount related to a load on the engine.
    Type: Application
    Filed: April 30, 2007
    Publication date: October 30, 2008
    Inventors: Kevin A. Bacon, Andrew J. Smith
  • Publication number: 20080261903
    Abstract: Reagents which regulate human RC Kinase activity and reagents which bind to human RC Kinase gene products can be used to regulate this protein for therapeutic effects. Such regulation is particularly useful for treating chronic obstructive pulmonary disease, asthma, cancer, and diseases in which cell signaling is defective.
    Type: Application
    Filed: June 16, 2004
    Publication date: October 23, 2008
    Inventors: Shinichi Watanabe, Jeffrey A. Encinas, Shinichi Kondo, Kevin Bacon
  • Patent number: 7375103
    Abstract: An optically active (?)-7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-5-[(3S)-3-piperidinyl]-1,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one of the formula (I) or salt thereof.
    Type: Grant
    Filed: March 3, 2003
    Date of Patent: May 20, 2008
    Assignee: Bayer HealthCare AG
    Inventors: Toshiki Murata, Sachiko Sakakibara, Takashi Yoshino, Hiroki Sato, Yuji Koriyama, Noriko Nunami, Megumi Yamauchi, Keiko Fukushima, Rolf Grosser, Kinji Fuchikami, Kevin Bacon, Timothy Lowinger
  • Publication number: 20080064736
    Abstract: The use of a compound of formula (I) or a salt thereof, where the symbols have the meanings given in the description, for the control of phytopathogenic mircroorganisms of harmful animals.
    Type: Application
    Filed: July 9, 2005
    Publication date: March 13, 2008
    Applicant: Bayer Cropscience AG
    Inventors: Stefan Hillebrand, Oliver Guth, Welf-Burkhard Wiese, Klaus Kunz, Astrid Ullmann-Koppold, Amos Mattes, Peter Schreier, Ulrike Wachnedorff-Neumann, Karl-Heinz Kuck, Peter Losel, Olga Malsam, Peter Reinemer, Marc Stadler, Stefan Seip, Anke Mayer-Bartschmid, Hartwig Muller, Kevin Bacon, Mark Drewes, Kerstin Ilg
  • Publication number: 20070155725
    Abstract: The present invention relates to a benzenesulfonamide derivative of formula (I), which is useful as an active ingredient of pharmaceutical preparations. The benzenesulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders. In said formula, X represents O or S; R4 represents formulae (a), (b), (c), (d), (e), (f), (g), (h), (i) or (j), the other substituents are as defined in claim 1.
    Type: Application
    Filed: March 11, 2004
    Publication date: July 5, 2007
    Inventors: Yingfu Li, Kevin Bacon, Hiromi Sugimoto, Keiko Fukushima, Kentaro Hashimoto, Makiko Marumo, Toshiya Moriwaki, Noriko Nunami, Naoki Tsuno, Klaus Urbahns, Nagahiro Yoshida
  • Publication number: 20070129355
    Abstract: The present invention relates to a pyrimidine derivative of the formula (I) and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The pyrimidine derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis.
    Type: Application
    Filed: April 14, 2004
    Publication date: June 7, 2007
    Applicants: ACTIMIS PHARMACEUTICALS, INC., BAYER AG, BAYER HEALTH CARE AG
    Inventors: Tai-wei Ly, Yuji Koriyama, Takashi Yoshino, Hiroki Sato, Kazuho Tanaka, Hiromi Sugimoto, Yoshihisa Manabe, Kevin Bacon, Klaus Urbahns, Masanori Seki, Takuya Shintani
  • Publication number: 20060275297
    Abstract: Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
    Type: Application
    Filed: July 28, 2006
    Publication date: December 7, 2006
    Inventors: Gerard Hardiman, Devora Rossi, Kevin Bacon, J. Bazan, Thomas Schall, Albert Zlotnik
  • Publication number: 20060229353
    Abstract: The present invention relates to substituted heterocycles, processes for their preparation, and their use in medicaments, especially for the treatment of inflammatory disease, i.e. asthma, or cancer.
    Type: Application
    Filed: February 6, 2004
    Publication date: October 12, 2006
    Inventors: Marc Stadler, Stephan Seip, Hartwig Müller, Anke Mayer-Bartschmid, Michael-Alexander Brüning, Jordi Benet-Buchholz, Hiroko Togame, Reiko Dodo, Peter Reinemer, Kevin Bacon, Kinji Fuchikami, Satoko Matsukawa, Klaus Urbahns
  • Patent number: 7091242
    Abstract: The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory diseases.
    Type: Grant
    Filed: October 8, 2001
    Date of Patent: August 15, 2006
    Assignee: Bayer Aktiengesellschaft
    Inventors: Thomas Rölle, Thomas Lehmann, Markus Albers, Gerhard Hessler, Gerhard Müller, Rüdiger Fischer, Masaomi Tajimi, Karl Ziegelbauer, Kevin Bacon, Haruki Hasegawa, Hiromi Okigami
  • Patent number: 7064229
    Abstract: The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory diseases
    Type: Grant
    Filed: June 24, 2002
    Date of Patent: June 20, 2006
    Assignee: Bayer Healthcare AG
    Inventors: Thomas Rolle, Thomas Lehmann, Markus Albers, Gerhard Muller, Gerhard Hessler, Rudiger Fischer, Masaomi Tajimi, Karl Ziegelbauer, Kevin Bacon, Haruki Hasegawa, Hiromi Okigami
  • Publication number: 20060128732
    Abstract: The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-? inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-? activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis.
    Type: Application
    Filed: September 18, 2003
    Publication date: June 15, 2006
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Mitsuyuki Shimada, Toshiki Murata, Kinji Fuchikami, Hideki Tsujishita, Naoki Omori, Issei Kato, Mami Miura, Klaus Urbahns, florian Gantner, Kevin Bacon
  • Publication number: 20050215547
    Abstract: An optically active (?)-7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-5-[(3S)-3-piperidinyl]-1,4-dihydro-2H-pyrido[2,3-d][1,3]?-azin-2-one of the formula (I) or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.
    Type: Application
    Filed: March 3, 2003
    Publication date: September 29, 2005
    Applicant: Bayer HealthCare AG
    Inventors: Toshiki Murata, Sachiko Sakakibara, Takashi Yoshino, Hiroki Sato, Yuji Koriyama, Noriko Nunami, Megumi Yamauchi, Keiko Fukushima, Rolf Grosser, Kinji Fuchikami, Kevin Bacon, Timothy Lowinger
  • Publication number: 20050070582
    Abstract: The present invention relates to a sulfonamide derivative which is useful as an active ingredient of pharmaceutical preparations. The sulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders.
    Type: Application
    Filed: September 4, 2002
    Publication date: March 31, 2005
    Applicant: Bayer Healthcare AG
    Inventors: Yingfu Li, Akihiko Watanabe, Timothy Lowinger, Kevin Bacon, Norihiro Kawamura, Takuya Shintani, Tetsuo Kikuchi, Toshiya Moriwaki, Klaus Urbahns, Keiko Fukushima, Noriko Nunami, Takashi Yoshino, Toshiki Murata, Megumi Yamauchi, Hiroko Yoshino
  • Publication number: 20050054582
    Abstract: The present invention relates to compounds of the general formula (I), their preparation and use as pharmaceutical compositions asintegrin antagonists, especially as ?4? and/or ?4?7 ?and/or ?9?1 intergrin antagonists and in particular for the production of pharmaceutical compositions suitable for the inhibition or the prevention of cell adhesion and cell-adhesion mediated disorders. Examples are the treatment and the prophylaxis of atherosclerosis, asthma, chronic obstructive pulmonary disease (COPD), allergies, diabetes, inflammatory bowel disease, multiple sclerosis, myocardial ischemia, rheumatoid arthritis, transplant rejection and other inflammatory, autoimmune and immune disorders.
    Type: Application
    Filed: September 20, 2002
    Publication date: March 10, 2005
    Inventors: Thomas Lehmann, Markus Albers, Thomas Rolle, Gerhard Hessler, Gerhard Hessler, Masaomi Tajimi, Karl Ziegelbauer, Hiromi Okigami, Kevin Bacon, Haruki Hasegawa
  • Publication number: 20040254157
    Abstract: The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory diseases.
    Type: Application
    Filed: August 4, 2004
    Publication date: December 16, 2004
    Inventors: Thomas Rlle, Thomas Lehmann, Markus Albers, Gerhard Muller, Gerhard Hessler, Rudiger Fischer, Masaomi Tajimi, Karl Ziegelbauer, Kevin Bacon, Haruki Hasegawa, Hiromi Okigami